H.C. Wainwright analyst Joseph Pantginis views Nightstar Therapeutics' (NITE) positive preliminary safety and efficacy data originated from its Phase 1/2 trial, which is testing NSR-RPGR for the treatment of X-linked retinitis pigmentosa in patients with the RPGR mutation, as a de-risking event for Applied Genetic's (AGTC) program. The Nightstar data represent "significant validation" for the ongoing Applied Genetic Phase 1/2 trial in XLRP in partnership with Biogen (BIIB), Pantginis tells investors in a research note. He keeps a Buy rating on the shares with an $8 price target.